Literature DB >> 27741021

Left Atrial Performance in the Course of Hypertrophic Cardiomyopathy: Relation to Left Ventricular Hypertrophy and Fibrosis.

Johannes T Kowallick1, Miguel Silva Vieira, Shelby Kutty, Joachim Lotz, Gerd Hasenfu, Amedeo Chiribiri, Andreas Schuster.   

Abstract

OBJECTIVES: Hypertrophic cardiomyopathy (HCM) is associated with left atrial (LA) functional abnormalities. The determinants and the degree of LA dysfunction in the course of HCM are not fully understood. We aimed to characterize LA mechanics in HCM, according to the extent of left ventricular (LV) hypertrophy and fibrosis. METHODS AND
RESULTS: Seventy-three HCM patients and 23 age- and sex-matched controls underwent cardiovascular magnetic resonance imaging including late gadolinium enhancement (LGE). LA reservoir, conduit, and contractile functions were quantified by fractional volume changes and cardiovascular magnetic resonance feature-tracking-derived strain and strain rate. In multivariable regression, LA mechanics were associated with the extent of LV LGE (P = 0.033 to P < 0.001), but not with the LV mass extent or maximum wall thickness (P = 0.108 to P = 0.964). Left atrial function decreased according to the increase in extent of LV fibrosis (non-LGE; mild LGE ≤ 10%; intermediate LGE 11%-19%; severe LGE ≥ 20%). Compared with healthy controls, LA conduit function was impaired in HCM with no LGE already (LA emptying fraction conduit: 32% ± 7% vs 26 ± 14, P = 0.037). Conversely, LA contractile booster pump function was impaired in HCM with severe LGE only (LA emptying fraction booster: 40% ± 8% vs 20% ± 10%, P < 0.001; for controls vs LGE ≥ 20%, respectively).
CONCLUSIONS: Left atrial functional abnormalities are associated with LV fibrosis, but not with LV hypertrophy. While LA conduit function is impaired in early HCM stages as represented by mild or absent LV fibrosis, LA contractile function is impaired later in the course of disease progression as demonstrated by the presence of severe LV fibrosis only. These novel markers of LA performance may potentially proof useful for disease staging and early detection of cardiac deterioration.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27741021     DOI: 10.1097/RLI.0000000000000326

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  16 in total

1.  Quantification of left atrial volume and phasic function using cardiovascular magnetic resonance imaging-comparison of biplane area-length method and Simpson's method.

Authors:  Laura Kristin Wandelt; Johannes Tammo Kowallick; Andreas Schuster; Rolf Wachter; Thomas Stümpfig; Christina Unterberg-Buchwald; Michael Steinmetz; Christian Oliver Ritter; Joachim Lotz; Wieland Staab
Journal:  Int J Cardiovasc Imaging       Date:  2017-05-18       Impact factor: 2.357

2.  Culprit vessel-related myocardial mechanics and prognostic implications following acute myocardial infarction.

Authors:  Sören J Backhaus; Johannes T Kowallick; Thomas Stiermaier; Torben Lange; Alexander Koschalka; Jenny-Lou Navarra; Joachim Lotz; Shelby Kutty; Boris Bigalke; Matthias Gutberlet; Hans-Josef Feistritzer; Gerd Hasenfuß; Holger Thiele; Andreas Schuster; Ingo Eitel
Journal:  Clin Res Cardiol       Date:  2019-07-05       Impact factor: 5.460

Review 3.  [MINOCA-myocardial infarction with nonobstructive coronary arteries].

Authors:  Johannes T Kowallick; Matthias Scholz; Andreas Schuster; Joachim Lotz
Journal:  Radiologie (Heidelb)       Date:  2022-10-13

4.  Comparison of Nonclassic and Classic Phenotype of Hypertrophic Cardiomyopathy Focused on Prognostic Cardiac Magnetic Resonance Parameters: A Single-Center Observational Study.

Authors:  Magdalena Stachera; Paweł Przybyło; Katarzyna Sznajder; Marek Gierlotka
Journal:  Diagnostics (Basel)       Date:  2022-04-28

5.  The Role of Left-Atrial Mechanics Assessed by Two-Dimensional Speckle-Tracking Echocardiography to Differentiate Hypertrophic Cardiomyopathy from Hypertensive Left-Ventricular Hypertrophy.

Authors:  Nicoleta-Monica Popa-Fotea; Miruna Mihaela Micheu; Nicoleta Oprescu; Adriana Alexandrescu; Maria Greavu; Sebastian Onciul; Roxana Onut; Ioana Petre; Alina Scarlatescu; Monica Stoian; Razvan Ticulescu; Diana Zamfir; Maria Dorobanțu
Journal:  Diagnostics (Basel)       Date:  2021-04-30

6.  Biatrial performance in children with hypertrophic cardiomyopathy: CMR study.

Authors:  Łukasz Mazurkiewicz; Lidia Ziółkowska; Joanna Petryka; Mateusz Śpiewak; Łukasz Małek; Agata Kubik; Magdalena Marczak; Jolanta Misko; Grażyna Brzezińska-Rajszys
Journal:  Eur Radiol       Date:  2018-06-07       Impact factor: 5.315

7.  Validation of a rapid semi-automated method to assess left atrial longitudinal phasic strains on cine cardiovascular magnetic resonance imaging.

Authors:  Shuang Leng; Ru-San Tan; Xiaodan Zhao; John C Allen; Angela S Koh; Liang Zhong
Journal:  J Cardiovasc Magn Reson       Date:  2018-11-05       Impact factor: 5.364

8.  A model based on clinical parameters to identify myocardial late gadolinium enhancement by magnetic resonance in patients with aortic stenosis: An observational study.

Authors:  Mariya Kuk; Simon Newsome; Francisco Alpendurada; Marc Dweck; Dudley J Pennell; Vassilios S Vassiliou; Sanjay K Prasad
Journal:  JRSM Cardiovasc Dis       Date:  2020-04-27

9.  Quantitative assessment of left ventricular mechanical dyssynchrony using cine cardiovascular magnetic resonance imaging: Inter-study reproducibility.

Authors:  Johannes T Kowallick; Geraint Morton; Pablo Lamata; Roy Jogiya; Shelby Kutty; Gerd Hasenfuß; Joachim Lotz; Amedeo Chiribiri; Eike Nagel; Andreas Schuster
Journal:  JRSM Cardiovasc Dis       Date:  2017-05-15

10.  Impact of Right Atrial Physiology on Heart Failure and Adverse Events after Myocardial Infarction.

Authors:  Andreas Schuster; Sören J Backhaus; Thomas Stiermaier; Jenny-Lou Navarra; Johannes Uhlig; Karl-Philipp Rommel; Alexander Koschalka; Johannes T Kowallick; Boris Bigalke; Shelby Kutty; Matthias Gutberlet; Gerd Hasenfuß; Holger Thiele; Ingo Eitel
Journal:  J Clin Med       Date:  2020-01-12       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.